Department of Neurology University of Duisburg-Essen Hufelandstrasse 55, 45122 Essen, Germany.
Ther Adv Neurol Disord. 2010 Mar;3(2):107-15. doi: 10.1177/1756285609359317.
The incidence of trigeminal neuralgia (TN) is 4.3 per 100,000 persons per year, with a slightly higher incidence for women (5.9/100,000) compared with men (3.4/100,000). There is a lack of certainty regarding the aetiology and pathophysiology of TN. The treatment of TN can be very challenging despite the numerous options patients and physicians can choose from. This multitude of treatment options poses the question as to which treatment fits which patient best. The preferred medical treatment for TN consists of anticonvulsant drugs, muscle relaxants and neuroleptic agents. Large-scale placebo-controlled clinical trials are scarce. For patients refractory to medical therapy, Gasserian ganglion percutaneous techniques, gamma knife surgery and microvascular decompression are the most promising invasive treatment options.
原发性三叉神经痛(TN)的发病率为每年每 10 万人 4.3 例,女性(5.9/10 万人)略高于男性(3.4/10 万人)。TN 的病因和发病机制尚不确定。尽管患者和医生可以选择多种治疗方法,但 TN 的治疗仍然极具挑战性。大量的治疗方法提出了一个问题,即哪种治疗方法最适合哪种患者。TN 的首选药物治疗包括抗惊厥药物、肌肉松弛剂和神经阻滞剂。大规模安慰剂对照临床试验很少。对于药物治疗无效的患者,经皮神经节 Gasserian 注射技术、伽玛刀手术和微血管减压术是最有前途的侵袭性治疗选择。